Your browser doesn't support javascript.
loading
Enhancing pediatric access to cell and gene therapies.
Mackall, Crystal L; Bollard, Catherine M; Goodman, Nancy; Carr, Casey; Gardner, Rebecca; Rouce, Rayne; Sotillo, Elena; Stoner, Rich; Urnov, Fyodor D; Wayne, Alan S; Park, Julie; Kohn, Donald B.
Afiliación
  • Mackall CL; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. cmackall@stanford.edu.
  • Bollard CM; Department of Pediatrics, Division of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA. cmackall@stanford.edu.
  • Goodman N; Department of Medicine, Division of Bone Marrow Transplant and Cell Therapy, Stanford University School of Medicine, Stanford, CA, USA. cmackall@stanford.edu.
  • Carr C; Center for Cancer and Immunology Research and Department of Pediatrics, Children's National Hospital and The George Washington University, Washington, DC, USA.
  • Gardner R; KidsVCancer, Washington, DC, USA.
  • Rouce R; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Sotillo E; St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Stoner R; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
  • Urnov FD; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Wayne AS; Exthymic, San Diego, CA, USA.
  • Park J; Innovative Genomics Institute, University of California at Berkeley, Berkeley, CA, USA.
  • Kohn DB; Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Nat Med ; 30(7): 1836-1846, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38886624
ABSTRACT
Increasing numbers of cell and gene therapies (CGTs) are emerging to treat and cure pediatric diseases. However, small market sizes limit the potential return on investment within the traditional biopharmaceutical drug development model, leading to a market failure. In this Perspective, we discuss major factors contributing to this failure, including high manufacturing costs, regulatory challenges, and licensing practices that do not incorporate pediatric development milestones, as well as potential solutions. We propose the creation of a new entity, the Pediatric Advanced Medicines Biotech, to lead late-stage development and commercialize pediatric CGTs outside the traditional biopharmaceutical model in the United States-where organized efforts to solve this problem have been lacking. The Pediatric Advanced Medicines Biotech would partner with the academic ecosystem, manufacture products in academic good manufacturing practice facilities and work closely with regulatory bodies, to ferry CGTs across the drug development 'valley of death' and, ultimately, increase access to lifesaving treatments for children in need.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia Genética / Tratamiento Basado en Trasplante de Células y Tejidos Límite: Child / Humans País/Región como asunto: America do norte Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia Genética / Tratamiento Basado en Trasplante de Células y Tejidos Límite: Child / Humans País/Región como asunto: America do norte Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos